TENX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended July 31, 2002, for Synthetic Blood International, Inc. (Note: The request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.). The company is classified as a Development Stage Company focused on pre-clinical product development. As of the reporting date, the company had 88,577,245 shares of common stock outstanding.

Key Financial Metrics

Note: The Statement of Operations in the filing text contains conflicting columns. The "Results of Operations" narrative confirms the 2002 quarterly expenses were $418,421 and the net loss was $400,194. The table above reflects these narrative-confirmed figures.

Material Changes vs. Prior Period

• Expense Reduction: Total expenses decreased by $147,368 compared to the prior year quarter. This was driven primarily by a $151,000 reduction in Research and Development (R&D) wages and contract consulting due to fewer animal studies in the current period.
• Net Loss Improvement: The net loss narrowed by $117,176 to $400,194. However, the improvement was less than the expense reduction due to a $30,192 decrease in interest income caused by falling interest rates and lower invested balances.
• Cash Position: Cash and cash equivalents decreased significantly from $4,009,613 in July 2001 to $2,020,701 in July 2002. This decline reflects ongoing operating cash burn and investing activities, partially offset by financing inflows in the prior year which were not present in the current quarter's financing section (which showed net cash used).
• Financing Activity: Unlike the prior year which saw cash provided by financing activities ($362,468), the current quarter saw cash used in financing activities ($55,139), primarily due to repayments of notes payable.

Outlook, Risks, and Management Commentary

• Liquidity Outlook: Management believes current cash reserves ($2.02 million) are sufficient to meet liquidity needs for the next 9 months. The company has no firm commitments for additional capital as of July 31, 2002.
• Development Stage: The company is in the pre-clinical trial stage. Significant additional financing is required for further development, testing, and potential FDA clinical trials.
• Strategic Partnerships: Projected capital requirements assume strategic partners will assume costs during Phase II clinical trials. If this does not occur, financing needs could increase substantially.
• Key Risks:
  • Inability to achieve results from pre-clinical studies or obtain FDA approval.
  • Failure to secure necessary financing, which could force delays, scaling back of programs, or selling technology rights.
  • Uncertainties regarding patent enforcement and potential infringement of third-party patents.
  • Challenges in scaling manufacturing and obtaining raw materials.
• Unusual Items: The filing text contains significant formatting inconsistencies in the "Statements of Operations" and "Cash Flows" tables, where columns for "Deficit Accumulated During Development Stage" appear to be misaligned with the "Three Months Ended" columns. The summary relies on the narrative "Results of Operations" section to clarify the actual quarterly figures.

Investor Verification Checklist

• Verify the company name discrepancy between the request metadata ("Tenax Therapeutics") and the filing text ("Synthetic Blood International, Inc.").
• Confirm the accuracy of the quarterly expense and loss figures ($418k expenses / $400k loss) against the narrative, as the financial tables in the source text appear to contain misaligned data columns.
• Assess the runway of 9 months based on the $2.02 million cash balance and current burn rate.
• Review the status of pre-clinical studies and any pending FDA communications not detailed in this summary.
• Investigate the nature of the "Notes Payable" and "Stockholder Notes" to understand debt covenants and repayment schedules.